Clinical Trials

MainTitle

LRAs United as a Novel Anti-HIV Strategy. (LUNA)

This study is currently recruiting participants. (see Contacts and Locations)

Verified May 2018 by Casper Rokx, Erasmus Medical Center

Sponsor
Erasmus Medical Center


Information provided by (Responsible Party)
Casper Rokx, Erasmus Medical Center

ClinicalTrials.gov Identifier
NCT03525730

First received: April 23, 2018
Last updated: May 3, 2018
Last Verified: May 2018
History of Changes
Purpose

Purpose

A translational proof of concept study in humans on the primary research question whether novel anti-human immunodeficiency virus (HIV) latency strategies, including a BAF inhibitor and a histone deacetylase inhibitor, result in HIV reservoir reduction in HIV patients on antiretroviral therapy.

Condition Intervention Phase
HIV-1-infection

Drug : Valproic Acid
Drug : Pyrimethamine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 6 week study, including 2 week intervention and 4 week post-treatment period.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LRAs United as a Novel Anti-HIV Strategy (LUNA): a Randomized Controlled Trial.

Further study details as provided by Casper Rokx, Erasmus Medical Center:

Primary Outcome Measures

  • Cell associated HIV-RNA [ Time Frame: 6 week ]
    The change in cell associated HIV-RNA between treatment initiation (week 0) and at the end of study (week 6). The change wil be compared between the study arms.
Secondary Outcome Measures:
  • Tat/rev induced limiting dilution assay (TILDA) [ Time Frame: 6 week ]
    The change in TILDA between the groups between week 2 and week 0, between week 6 and week 2, and between week 6 and week 0 The change will be compared between the study arms.
  • Synergy [ Time Frame: 6 week ]
    Potential synergism or additive effects of the administration of both drugs will be assessed by performing separate models including either both treatments or separate and subsequently investigating which model best predicts the outcome. the Bliss independence method to assess synergism will be performed. The combination therapy is considered synergistic if the difference and its 95% normal confidence interval (CI) were >0.
  • Cell associated HIV-RNA [ Time Frame: 6 week ]
    The change in cell associated HIV-RNA between and within the groups between week 2 and week 0, between week 6 and week 2, and between week 6 and week 0.
  • Cell associated HIV-DNA [ Time Frame: 6 week ]
    The change in cell associated HIV-DNA between and within the groups between week 2 and week 0, between week 6 and week 2, and between week 6 and week 0.
  • Plasma HIV-RNA [ Time Frame: 6 week ]
    The change in plasma HIV-RNA between and within the groups between week 2 and week 0, between week 6 and week 2, and between week 6 and week 0.
  • Histone deacetylation [ Time Frame: 6 week ]
    The change in the level of histone acetylation between and within the groups between week 0 and week 2, and between week 2 and week 6.
  • Expression of BAF subunits [ Time Frame: 6 week ]
    The change in the level of expression between and within the groups between week 0 and week 2, and between week 2 and week 6.
  • Immunological functionality [ Time Frame: 6 week ]
    The change of the functionality of innate immune cells, HIV specific CD4+ and CD8+ T cells and HIV specific B-cells between and within the groups between week 0 and week 2, and between week 2 and week 6.
  • Immunological cytotoxicity [ Time Frame: 6 week ]
    The change of the cytotoxicity of innate immune cells, HIV specific CD4+ and CD8+ T cells and HIV specific B-cells between and within the groups between week 0 and week 2, and between week 2 and week 6.
  • Immunological phenotype [ Time Frame: 6 week ]
    The change of the phenotype of innate immune cells, HIV specific CD4+ and CD8+ T cells and HIV specific B-cells between and within the groups between week 0 and week 2, and between week 2 and week 6.
  • Reservoir biomarkers [ Time Frame: 6 week ]
    The correlations between clinical markers, markers of the viral reservoir (HIV-DNA, HIV-RNA), frequency and functionality of immune cells, cytokines, and level of acetylation/BAF expression with the change in reservoir (cell asociated-HIVRNA and TILDA) within and between the treatment arms
  • In vivo/ex vivo reservoir reactivation correlation [ Time Frame: 6 week ]
    The correlation between ex vivo/in vitro (primary CD4 T cells, and cell line based) LRA efficacy, assessed using the size of the reservoir as measured by TILDA, HIV-DNA, HIV-RNA and level of acetylation/BAF expression after stimulation by pyrimethamine, valproic acid or both, and this will be correlated to these observed reservoir measurements outcomes in vivo at week 2 and week 6.
  • Incidence of Treatment-Emergent Adverse Events [ Time Frame: 6 week ]
    The clinical and biochemical adverse events will be assessed by the Common Toxicity Criteria.
  • Plasma HIV-RNA [ Time Frame: 6 week ]
    The proportion of subjects with plasma HIV-RNA >=20, >=50, >=200 at weeks 0, weeks 2 and week 6.
  • Pharmacokinetics of dolutegravir [ Time Frame: 6 week ]
    Plasma concentrations Cmax dolutegravir will be measured using validated methods in patients receiving these medications. The pharmacokinetic profiles of the dolutegravir will be assessed in relation to the primary endpoint and use of valproic acid.
  • Pharmacokinetics of dolutegravir [ Time Frame: 6 week ]
    Plasma concentrations Ctrough dolutegravir will be measured using validated methods in patients receiving these medications. The pharmacokinetic profiles of the dolutegravir will be assessed in relation to the primary endpoint and use of valproic acid.
  • Pharmacokinetics of valproic acid [ Time Frame: 6 week ]
    Plasma concentrations Ctrough of valproic acid will be measured using validated methods in patients receiving these medications. The total and free (nonprotein-bound) plasma concentrations of valproic acid will be measured. The pharmacokinetic profiles of the investigational medical products will be assessed in relation to the primary endpoint.
  • Pharmacokinetics of valproic acid [ Time Frame: 6 week ]
    Plasma concentrations Cmax of valproic acid will be measured using validated methods in patients receiving these medications. The total and free (nonprotein-bound) plasma concentrations of valproic acid will be measured. The pharmacokinetic profiles of the investigational medical products will be assessed in relation to the primary endpoint.
  • Pharmacokinetics of pyrimethamine [ Time Frame: 6 week ]
    Plasma concentrations Cmax of pyrimethamine will be measured using validated methods in patients receiving this medication. The pharmacokinetic profiles of the investigational medical products will be assessed in relation to the primary endpoint.
  • Pharmacokinetics of pyrimethamine [ Time Frame: 6 week ]
    Plasma concentrations Ctrough of pyrimethamine will be measured using validated methods in patients receiving this medication. The pharmacokinetic profiles of the investigational medical products will be assessed in relation to the primary endpoint.

Estimated Enrollment: 28
Study Start Date: April 18, 2018
Estimated Study Completion Date: April 2020
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
No Intervention: Control
This group receives no intervention.
Experimental: Valproic acid
This group receives valproic acid (enteric) for 14 days.
Drug: Valproic Acid

Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.

Other Name: Depakine
Experimental: Pyrimethamine
This group receives pyrimethamine for 14 days.
Drug: Pyrimethamine

Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.

Other Name: Daraprim
Experimental: Valproic acid and Pyrimethamine
This group receives valproic acid and pyrimethamine for 14 days.
Drug: Valproic Acid

Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.

Other Name: Depakine
Drug: Pyrimethamine

Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.

Other Name: Daraprim

Detailed Description:

The retrovirus HIV integrates as proviral DNA in the genome of cluster of differentiation (CD)4+ T cells. A subset form a reservoir of latently infected long-lived memory T-cells with nearly absent HIV-DNA transcription. This persistent latent HIV reservoir is the major obstacle for a cure. HIV latency is sustained by multiple host factors that restrict the viral promotor and expression of the viral genome. Latency reversing agents (LRA) can remove these restrictive components and mediate HIV latency reversal. LRA monotherapy with histone deacetylase inhibitors (HDACi) alone, including valproic acid, vorinostat, romidepsin, or panobinostat, reactivate HIV but seems insufficient to eliminate the reservoir in vivo. Our research group has identified the BAF complex as another repressive factor that maintains HIV latency. Pyrimethamine acts as an inhibitor of this BAF complex, is capable of reactivating HIV from latency at clinical tolerable concentrations, and acts synergistic with other LRA classes. This offers new opportunities for cure research. This is the first translational clinical study with BAF inhibitors and it assesses the potential synergism of 2 LRA with different modes of action on the reservoir in HIV patients.
Primary objective:
The longitudinal assessment of the effects of the BAF inhibitor pyrimethamine and of the HDACi valproic acid on the HIV reservoir in HIV patients on antiretroviral therapy.
Study design:
Open label 6 week randomized controlled intervention trial.
Study population:
Participants must be HIV infected, ≥18 years and on antiretroviral therapy with plasma HIV-RNA <50 copies/mL and CD4+ T cell count ≥200 cells/mm3 at enrollment. The HIV-RNA was ≥10.000 copies/mL before antiretroviral therapy initiation.
Intervention:
Participants are randomized to either of 4 arms and receive valproic acid, pyrimethamine, both for 2 weeks, or no intervention. Total study duration is 6 weeks and includes a 2 week treatment period and a 4 week post-treatment period.
Primary endpoint:
The change in HIV reactivation in the reservoir in vivo at treatment initiation and at the end of treatment, measured as the change in cell associated HIV-RNA. The change in reactivation is compared between the treatment arms.
Secondary endpoints:
See below.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

    1. HIV-1 infected patients ≥18 years.
    2. World Health Organization (WHO) performance status 0 or 1.
    3. Confirmed HIV-1 infection by 4th generation ELISA, Western Blot or PCR.
    4. Wild type HIV infection or polymorphisms associated with at highest low-level resistance to any class of ART according to Stanford HIV drug resistance database.
    5. On cART.
    6. Current plasma HIV-RNA <50 copies/mL for at least 365 days and measured on at least 2 occasions of which at least 1 must be obtained within 365 and 90 days prior to study entry.
    7. Current CD4 T-cell count at study entry of ≥200 cells/mm3.
    8. Pre-cART HIV-RNA ≥10.000 copies/mL.


Exclusion Criteria:
    1. Previous virological failure, defined as either acquired resistance mutations on cART or HIV-RNA >1000 copies/mL on two consecutive measurements during cART.
    2. Uncontrolled hepatitis B or C co-infection. For hepatitis B: patients should be vaccinated, or on pre-exposure prophylaxis through the use of lamivudine/emtricitabine or tenofovir in their combination ART. Otherwise, standard serological testing should be available within the last 365 days for homosexual HIV positive men. For non-homosexual HIV positive persons, there should be at least one negative hepatitis B test (either by serology or PCR). For homosexual HIV positive men, a negative hepatitis C immunoglobulin G, hepatitis C (HCV) antigen, blot or HCV-RNA PCR should be available within the previous 365 days. For non-homosexual HIV positive persons, there should be at least one negative hepatitis C test (either IgG, blot or PCR) available.
    3. Prior exposure to any HDACi, BAFi or other known LRA.
    4. Prior exposure to cytotoxic chemotherapy during cART.
    5. Concurrent exposure to strong interacting medication on glucuronidation.
    6. Exposure within 90 days prior to study entry to immunomodulators, cytokines, systemic antifungals, dexamethasone, vitamin K antagonists, anti-epileptics, antipsychotics, carbapenems, mefloquine, colestyramine, Any documented opportunistic infection related to HIV in the last 90 days.
    7. Inadequate blood counts, renal and hepatic function tests
      1. Haemoglobin <6.5 mmol/L (males) or <6.0 mmol/L (females), leucocytes <2.5 x109/L, absolute neutrophil count <1000 cells/mm3, thrombocytes <100 x109/L, international standardized ratio >1.6, activated partial thromboplastin time >40 seconds.
      2. Estimated glomerular filtration rate <50 mL/min (CKD-EPI),
      3. Alanine aminotransferase or total bilirubin >2.5x upper limit of normal.
      4. All laboratory values must be obtained within 42 days prior to the baseline visit.
    8. Megaloblastic anemia due to folate deficiency.
    9. Pancreatitis in last 6 months, or chronic pancreatitis.
    10. Active malignancy during the past year with the exception of basal carcinoma of the skin, stage 0 cervical carcinoma, Kaposi Sarcoma treated with cART alone, or other indolent malignancies.
    11. Females in the reproductive age cannot participate. Males cannot participate if they refuse to abstain from sex or condom use in serodiscordant sexual contact during the study, except if their sexual partner(s) use pre-exposure prophylaxis.
    12. Patients with active substance abuse or registered allergies to the investigational medical products.
    13. Last, any other condition (familial, psychological, sociological, geographical) which
    in the investigator's opinion poses an unacceptable risk or would hamper compliance with the study protocol and follow up schedule, will prohibit participation.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03525730

Contacts

Contact:   Casper Rokx, MD PhD +31681336328 c.rokx@erasmusmc.nl

Locations

Netherlands
Erasmus MC Recruiting
Rotterdam, Netherlands, 3015 CN
Contact: Casper Rokx, MD PhD    +31681336328    c.rokx@erasmusmc.nl
Sub-Investigator: Henrieke Prins, MD
Sub-Investigator: Jeroen van Kampen, MD PhD
Sub-Investigator: Yvonne Muller, PhD
Sub-Investigator: Tokameh Mahmoudi, PhD
Sub-Investigator: Charles Boucher, MD PhD
Sub-Investigator: Annelies Verbon, MD PhD
Sub-Investigator: David Burger, PHD

Sponsors and Collaborators

Erasmus Medical Center

Investigators

Principal Investigator: Casper Rokx, MD PhD Erasmus Medical Center
More Information

More Information


Responsible Party: Casper Rokx, MD PhD, Erasmus Medical Center  
ClinicalTrials.gov Identifier: NCT03525730   History of Changes  
Other Study ID Numbers: 2017-002837-48  
Study First Received: April 23, 2018  
Last Updated: May 3, 2018  
Individual Participant Data    
Plan to Share IPD: Undecided  

Studies a U.S. FDA-regulated Drug Product: No  
Studies a U.S. FDA-regulated Device Product: No  
Product Manufactured in and Exported from the U.S.: Yes  

Keywords provided by Casper Rokx, Erasmus Medical Center:

HIV
Latency reversing agents
HDAC inhibitor
BAF inhibitor
HIV reservoir
HIV cure

Additional relevant MeSH terms:
Pyrimethamine
Valproic Acid

ClinicalTrials.gov processed this data on November 22, 2019
This information is provided by ClinicalTrials.gov.